Maintenance Therapies for Patients with Non-Small Cell Lung Cancer

Cilta-cel therapy significantly enhances survival rates in lenalidomide-refractory multiple myeloma, outperforming standard treatments in recent trials.

During a live event, Saby George, MD, and participants discussed tolerability concerns in patients with recurrent renal cell carcinoma who received prior immune checkpoint inhibitor.

Discover essential strategies for physicians to enhance team management in medical practices, fostering efficiency and improving patient care.

In separate, live virtual events, William J. Gradishar, MD; and Tiffany A. Traina, MD, discussed multiple scenarios for a patient with hormone receptor–positive, HER2-negative breast cancer to potentially receive hormonal plus endocrine therapy.

Tabelecleucel shows promising efficacy in treating EBV-positive PTLD, offering hope for patients resistant to previous therapies.

The safety and efficacy outcomes of a total of 3 CD19-directed CAR T-cell therapies were confirmed with other real-world data with CAR T-cell therapy in patients with B-cell malignancies.